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Objectives: Elevated levels of C-reactive protein are one of the strongest prognostic
factors in atherosclerosis. In addition to predicting vascular disease, C-reactive
protein may directly facilitate the development of a proinflammatory and proath-
erosclerotic phenotype. Recent studies have demonstrated marked up-regulation of
various adhesion molecules and inflammatory responses in endothelial cells sub-
jected to C-reactive protein. The nuclear factor-B signal transduction is known to
play a key role in the expression of these proatherogenic entities. This study
examines the direct effects of C-reactive protein on nuclear factor-B activation and
related mechanisms in saphenous vein endothelial cells.
Methods: The activation of nuclear factor-B was determined by confocal micros-
copy assessing the nuclear localization of nuclear factor-B in endothelial cells
incubated with C-reactive protein (50 g/mL) for 30 minutes and 3 hours. Cells not
incubated with C-reactive protein were used as negative controls, and cells incu-
bated with tumor necrosis factor- (10 ng/mL) for 15 minutes were used as positive
controls in all studies. The degradation of IB- and IB- was assessed by
Western blotting of the cell lysates obtained from cells incubated with human
recombinant C-reactive protein (50 g/mL) for 15 minutes, 30 minutes, and 1 hour.
Results: Nuclear factor-B nuclear translocation in endothelial cells increased
significantly after 30 minutes of incubation with C-reactive protein (P  .01).
Nuclear localization of nuclear factor-B returned to baseline levels after 3 hours of
incubation with C-reactive protein. Incubation with C-reactive protein resulted in
degradation of IB- that was maximal at 30 minutes (P  .05). C-reactive protein
showed no significant effect on IB- degradation.
Conclusions: These data demonstrate, for the first time, that C-reactive protein
activates the nuclear factor-B signal transduction pathway in endothelial cells.
Degradation of IB-, but not IB-, seems to be the major pathway leading to
nuclear factor-B nuclear translocation and activation induced by C-reactive pro-
tein. These data support the concept that C-reactive protein, at concentrations known
to predict diverse vascular insults, directly facilitates a proinflammatory and proath-
erosclerotic phenotype through activation of nuclear factor-B. These data have
important implications for saphenous vein atherosclerosis in patients with elevated
C-reactive protein levels.
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The advances in basic science in the past fewyears have established a fundamental rolefor inflammation in mediating all stages ofatherosclerosis from initiation through pro-gression and ultimate thrombotic complica-tions.1 C-reactive protein (CRP) is one of the
most powerful predictors of myocardial infarction, stroke,
and vascular death currently known2-9 and has recently been
demonstrated to have a predictive value for cardiovascular
events exceeding that of low-density lipoprotein (LDL)-
cholesterol.10 Recent studies further indicate that CRP is not
only an inflammatory marker of atherosclerosis and coro-
nary events but also a mediator of atherosclerosis, because
it has been demonstrated to markedly up-regulate the ex-
pression of cell adhesion molecules and inflammatory re-
sponses related to atherosclerosis.11-14
Nuclear factor (NF)-B has been implicated as a key
mediator of atherosclerosis.15-17 Most proinflammatory
genes expressed in endothelial cells (ECs) during the initial
phase of lesion formation and in response to inflammatory
mediators are dependent on NF-B activation.18 Because
CRP up-regulates the production of a number of endothelial
adhesion molecules known to be transcriptionally activated
by NF-B,13,19,20 this study investigated the direct effects of




Human saphenous vein ECs were harvested from vein segments
obtained from patients undergoing bypass surgery and were grown
in Iscove’s modified Dulbecco’s medium supplemented with 10%
fetal bovine serum. ECs were plated onto 60-mm plates and grown
to confluence before treatment. ECs between passages 2 and 4
were used for the studies outlined next. Human recombinant CRP
(Calbiochem, San Diego, Calif) was used in all studies described.
Given the concern surrounding the potential contamination of CRP
with endotoxin, a number of control experiments were performed
as described previously,12 and all studies were performed in the
presence of polymyxin-B (50 g/mL, Sigma-Aldrich, St Louis,
Mo).
Confocal Microscopy
The activation of NF-B was determined by confocal microscopy
assessing the nuclear localization of NF-B in cells incubated with
CRP (50 g/mL) for 30 minutes and 3 hours. Cells not incubated
with CRP were used as negative controls, and cells incubated with
tumor necrosis factor (TNF)- (10 ng/mL, Sigma-Aldrich) for 15
minutes were used as positive controls in all studies. Cells were
stained using a 1:500 dilution of primary antibody for p65 (sc-372,
Santa Cruz Biotechnology Inc, Santa Cruz, Calif), a subunit of
NF-B, which is abundant in the cytoplasm. Tyramide signal
amplification (NEN Life Science Products, Boston, Mass) was
used to detect p65 according to the manufacturer’s protocol. Pri-
mary antibody incubation was for 2 hours at room temperature.
Subsequent incubations were biotin-conjugated secondary anti-
body for 30 minutes, streptavidin-conjugated horseradish peroxi-
dase for 30 minutes, and fluorescein isothiocyanate-conjugated
tyramide complex for 8 minutes. Tris-HCl blocking buffer (NEN)
was used for diluting antibodies and washes. Nuclei were coun-
terstained with propidium iodide (Sigma-Aldrich).
Images of the ECs were taken using a Bio-Rad MRC-1024ES
confocal microscopy (Hercules, Calif) with a krypton and argon
laser. In every experimental group, 5 images were obtained from
different regions of the stained slides. Confocal settings were
optimized and maintained for all images obtained. Fluorescent
staining and NF-B nuclear translocation were quantified using
pixel distribution data from the confocal images to indicate the
percentage of pixels positive for both p65 and nuclear stain to
indicate the percentage of nuclei with translocated p65.
Western Blotting
The effects of CRP on the degradation of IB- and IB- were
determined by Western blotting with the use of IB- and IB-
polyclonal antibodies (sc-1643 and sc-945, Santa Cruz Biotech-
nology Inc). Briefly, EC lysates obtained from cells incubated with
CRP (50 g/mL) for 15 minutes, 30 minutes, and 1 hour or with
TNF- (10 ng/mL) for 15 minutes were fractionated through a 4%
stacking and 10% running sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gel, and the fractionated proteins were trans-
ferred to polyvinylidene difluoride membranes. Blots were blocked
for 1 hour at room temperature with blocking buffer (5% nonfat
milk in 10 mmol/L Tris pH 7.5, 100 mmol/L NaCl, 0.1% Tween
20). Rabbit anti-angiotensin II receptor type 1 and type 2 poly-
clonal immunoglobulin Gs (Transduction Laboratories, Lexington,
Ky), at a dilution of 1:200, were reacted with the blots overnight
at 4°C. After washing 2 for 15 minutes in 1 TTBS (Tris-
buffered saline with 0.05% Tween 20), the blots were incubated
with the secondary antibody (horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulin antibody (Santa Cruz Biotechnol-
ogy Inc) at 1:2000 dilution for 1 hour at room temperature.
Visualization was performed with the use of enhanced chemilu-
minescence. Densitometric analysis of Western blots was per-
formed with the use of PDI Imageware System (San Diego, Calif).
Statistical Analysis
The results are presented as mean  SD. Statistical comparisons
were performed by analysis of variance followed by Dunn’s mul-
tiple contrast hypothesis test to identify differences between var-
ious treatments or by the Mann-Whitney U test.
Results
Activation of NF-B
At baseline, ECs stained for p65 showed an abundance of
this NF-B subunit in the cytoplasm (Figure 1, A). After
ECs were stimulated with human recombinant CRP (50
g/mL) for 30 minutes, p65 nuclear translocation signifi-
cantly increased by 4.5-fold (P  .01) and then returned to
baseline after 3 hours, indicating an early phase activation
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of NF-B in these cells (Figure 1). The positive control,
TNF- (10 ng/mL) stimulation for 15 minutes, induced a
3.5-fold increase in p65 nuclear translocation (P  .05
compared with the negative control) (Figure 1).
Western Blotting of IB- and IB-
Incubation with CRP (50 g/mL) resulted in an increased
degradation of IB- that was first observed at 15 minutes
and was maximal at 30 minutes (P  .05) (Figure 2, A).
This effect of CRP slightly decreased at 1 hour. In the
positive control group, TNF- significantly increased the
degradation of IB- at 15 minutes (Figure 2, A). CRP
showed no significant effect on IB- degradation; how-
ever, TNF- (10 ng/mL) significantly increased the degra-
dation of IB- (P  .01) (Figure 2, B).
Figure 1. A, Representative immunoconfocal images of control ECs. ECs stimulated with human recombinant CRP
(50 g/mL) for 30 minutes and 3 hours or the positive control, TNF- (10 ng/mL), for 15 minutes. Cells were stained
for p65, a subunit of NF-B (green), which is abundant in the cytoplasm. Nuclei were counterstained with
propidium iodide. Increased p65 nuclear translocation occurs with cells stimulated with CRP for 30 minutes, and
this response disappears by 3 hours. B, Fluorescent staining is quantified using pixel distribution data from
confocal images to indicate the percentage of pixels positive for both p65 and nuclear stain (propidium iodide) to
indicate the percentage of nuclei with translocated p65 (n  5). (*P < .05 different from control.) CRP, C-reactive
protein; TNF, tumor necrosis factor.
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Discussion
During the past few years we have witnessed a paradigm
shift in our understanding of the underlying principles of
atherosclerosis. This “new view” supports the concept that
vascular inflammation is the central orchestrator of athero-
sclerotic lesion formation, progression, and eventual rup-
ture.1 This paradigm shift has fueled exponentially increas-
ing interest in evaluating inflammatory markers of
atherosclerosis, of which high-sensitivity CRP has emerged
as one of the most important.2-7 As such, the inflammatory
marker CRP is one of the most powerful independent pre-
dictors of myocardial infarction, stroke, and vascular death
in a variety of settings. This acute-phase reactant has also
been shown to predict future coronary events and portend
the vulnerability of an atherosclerotic lesion and the likeli-
hood of plaque rupture. During the past year, much interest
has been generated in unraveling the mechanistic basis of
the CRP and atherosclerosis connection. Indeed, recent
studies, including work from our group, suggest that CRP is
not only a predictor but also an active partaker in lesion
formation.11-14,19,20 CRP, at concentrations known to pre-
dict vascular disease, has a direct effect on stimulating
diverse early atherosclerotic processes including EC adhe-
sion molecule expression, chemoattractant chemokine se-
cretion, and macrophage LDL uptake.13,19,20 At the level of
vascular smooth muscle, CRP directly stimulates the angio-
tensin-type 1 receptor and promotes smooth muscle cell
proliferation, migration, and neointimal formation in vitro
and in vivo.14 Thus, CRP is not only an inflammatory
marker of atherosclerosis and coronary events but also a
mediator of the disease, because it contributes to the sub-
strate underlying lesion formation, plaque rupture, and cor-
onary thrombosis through interaction with and alteration of
the vascular phenotype.
NF-B has been implicated as a key mediator of athero-
sclerosis.15-17 This transcription factor is a DNA binding
protein complex that is usually present in the cytosol as an
inactive complex. IB, an associated protein, renders this
complex inactive by shielding the nuclear localization sig-
nal.21 Although several inhibitor proteins have been identi-
fied (IB-, IB-, IB-, and p105), IB- is the best
characterized form of IB.16 On IB phosphorylation and
its subsequent degradation, the heterodimeric NF-B com-
plex translocates from the cytoplasm to the nucleus, where
it binds to specific DNA sequences in the promoter region
of several genes and up-regulates their transcription. Mul-
tiple genes whose products are putatively involved in the
atherosclerotic process are regulated by NF-B.18 Tran-
scriptional activation of the genes encoding the cell adhe-
sion molecules (vascular cell adhesion molecule-1, intracel-
lular adhesion molecule-1, E-selectin) and chemokines
(monocyte chemoattractant protein-1) are tightly regulated
by the transcription factor NF-B. The present study dem-
onstrates that CRP directly increases the degradation of
IB- and subsequently activates the NF-B pathway.
Activation of NF-B has been linked to protection
against apoptosis in certain circumstances.22-24 However,
CRP has been shown to facilitate EC apoptosis.12 The
findings in the present study showed that increased p65
nuclear translocation rapidly and transiently occurred with
ECs stimulated with CRP for 30 minutes, and that this
response disappeared by 3 hours. This transient increase of
NF-B likely activates the expression of a number of the
proatherogenic factors but does not have protective effects
on EC apoptosis during later phases.
These data demonstrate, for the first time, that CRP
directly activates the NF-B signal transduction pathway in
saphenous vein ECs. Degradation of IB-, but not IB-,
seems to be the major pathway leading to NF-B nuclear
Figure 2. IB- (A) and IB- (B) protein levels in unstimulated
control human saphenous vein ECs. Cells stimulated with human
recombinant CRP (50 g/mL) for 15 minutes, 30 minutes, and 1
hour or the positive control, TNF- (10 ng/mL), for 15 minutes (n 
5). Protein levels were assessed by Western blotting of cell
lysate. (*P < .05 different from control.)
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localization and activation induced by CRP. These data
support the growing body of evidence indicating that CRP is
not only a marker but also an active mediator of atheroscle-
rotic lesion formation and that patients with elevated levels
of CRP may be at increased risk of saphenous vein athero-
sclerosis.
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Discussion
Dr Alexander Wahba (Trondheim, Norway). Do you know
why some patients would have a high CRP compared with other
patients? What would your target be, and how would you try to
treat this?
Dr Verma. It is unclear what the receptor is on the endothelium
that mediates all of these pleiotropic effects of CRP. We have
performed some preliminary work with this, and we suggest that it
is the LOX1 (Lectin-like oxidized low-density lipoprotein receptor
1) receptor, the receptor that was originally defined to bind oxi-
dized LDL. The LOX1 receptor now seems to bind a number of
structurally distinct molecules, including apoptotic cells, and some
preliminary data from our group indicate that CRP strongly binds
to LOX1 and that LOX1 antagonists block the proatherogenic
effects of CRP.
Dr Wahba. What is the cause for having a high CRP?
Dr Verma. The cause for an elevated CRP usually reflects
underlying inflammation and is a surrogate for the underlying
atherosclerotic process. Risk factors, both genetic and acquired,
influence CRP, as does ethnicity.
Dr Carmelo A. Milano (Durham, NC). That was an excellent
presentation and a lot of data. I was wondering if you could speak
a little bit about the dose of CRP you used in these in vitro studies.
Do you have a mechanism by which you can correlate that to what
CRP levels might be in vivo in a patient or an animal?
Dr Verma. We have looked at CRP concentrations from 1 to
100 g/mL, and the reason for using those CRP concentrations is
because those are really the values that seem to predict future
cardiovascular events.
Dr Jakob Vinten-Johansen (Atlanta, Ga). That was a beauti-
ful study. It really should leave something for the rest of us to do.
Have you tried the concept in vivo? Have you looked at
whether CRP, for example, increases neutrophil adherence, migra-
tion, and so forth, and then have you tried it in an in vivo
saphenous vein model graft?
Dr Verma. We have performed in vivo carotid angioplasty
experiments in the presence and absence of continuous CRP ad-
ministration and demonstrated at a 4-week time point that there
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was increased vascular smooth muscle cell migration and prolif-
eration by bromodeoxyuridine staining. That actually correlates
very nicely with increased intimal medial thickness and angioten-
sin-1 receptor density.
The reason why we cannot perform experiments exceeding 4
weeks in rats is the way we perform the experiments. We give 2
local injections of CRP at the site and then use a gelling agarose
gel to keep the CRP at the site of injury, and what we have noticed
is that after 6 weeks we start losing that effect; thus, we chose the
4-week time point to mimic a long-term model of high CRP.
Dr Y. Joseph Woo (Philadelphia, Pa). That was a great study.
You postulated several different mechanisms. Would you elabo-
rate on the potential role for the increased elimination of the
endothelial progenitor cells and what that might have to do with
the overall mechanism?
Dr Verma. I think there are 2 mechanisms operating here.
First, there are direct proatherogenic effects that promote not only
atherosclerosis at the level of the endothelium but also neoin-
timal hyperplasia at the level of the vascular smooth muscle,
and we believe that the unifying hypothesis is mediated through
LOX1.
The effects of CRP on endothelial progenitor cells are probably
a completely distinct mechanism through which CRP not only
promotes atherosclerosis but also inhibits the compensatory mech-
anism in atherosclerosis (ie, the recruitment and homing of bone
marrow-derived progenitor cells inhibiting angiogenesis).
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